engleski

Transfusion therapy of patients with malignant lymphomas

Out of 607 consecutive patients with malignant lymphomas treated at our Department between January 1990 and May 1995, 112 (18%) received blood components Transfusion. There were 88 patients with non-Hodgkin's lymphoma (NHL), and 24 patients with Hodgkin's disease (MH). According to Kiel classification, low-grade malignancy NHL was diagnosed in 36 (41%) patients, and high-grade malignancy NHL in 52 (59%) patients. According to the immune finding of lymph node, 67 patients (76%) had B-cell NHL, and 21 patients (24%) had T-cell NHL. All together 697 units of red blood cell (RBC) concentrates (on average 6.22 units per patient) and 1612 units of platelet (PLT) concentrates (on average 14.39 units per patient) were transfused to patients with malignant lymphomas during the period we studied. Distribution of blood components use showed a greater need for RBC concentrates than for platelet concentrates. The requirement for blood Transfusion support was statistically significantly higher (p<0.05) in patients with NHL, than in patients with MH. Patients with high-grade malignancy NHL showed a greater need for RBC and platelet transfusions than low-grade malignancy NHL (p<0.05). The difference in the requirement for blood components between patients with B-cell NHL and those with T-cell NHL was not statistically significant. These results can be useful in planning of Transfusion support.

malignant lymphomas; blood components; transfusion

nije evidentirano